Friday, 6 November 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 8, 2026

Stock market today: Dow rises, S&P 500 and Nasdaq drop as defense stocks surge, tech slides

View original at finance.yahoo.com
Stock market today: Dow rises, S&P 500 and Nasdaq drop as defense stocks surge, tech slides US stocks moved mostly lower on Thursday, retreating further from all-time highs as investors took in fresh labor market data and grappled with President Trump's salvos on defense and Venezuela…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The jobs market got a positive sign to end a rather gloomy year, with planned layoff announcements hitting their lowest level of 2025 in December

    80% confidence

  • The world is set to face a critical copper shortage, driven by a boom in AI and defense spending, with global demand to grow by 50% by 2040

    80% confidence

  • US oil companies would be reimbursed if they invested in Venezuela

    80% confidence

  • The US could oversee Venezuela and control its oil revenue for years, potentially indefinitely going forward

    80% confidence

  • Trump threatened to block share buybacks and dividend payments by US defense majors if they didn't invest in ramping up weapons operations

    80% confidence

  • Trump wants to boost military spending by 50% to $1.5 trillion a year, funded by proceeds from tariffs

    80% confidence

  • H200 sales to China would be materially additive to earnings for NVDA

    80% confidence

  • The US will lift export restrictions on Nvidia's H200 AI chips in December in exchange for a cut of its revenue

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com